SOPHARMA AD

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 7 / 2023

Date of issue: 2023-01-27

Short name of the issuer

SOPHARMA AD

Subject

"Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD

Official market - legal basis

art. 56. 1. 2 of Act on Public Offering.

Unofficial market - legal basis

Contents of the report:

“Sopharma” AD (the Company) notifies that in compliance with the decision of the Board of Directors of "Sopharma" AD dated 26.10.2022, the Company submitted for approval to the Financial Supervision Commission an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD, UIC: 119055339 in "Sopharma“ AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on Public Offering of Securities.

Annexes

File Description

SFA_2023_Biopharm_merger_FSC_FF_espi.pdf "Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2023-01-27 Ognian Donev Executive Director